Mitsubishi UFJ Trust & Banking Corp Sells 111,862 Shares of Sabra Healthcare REIT, Inc. $SBRA

Key Points

• Mitsubishi UFJ Trust & Banking Corp cut its stake in Sabra Healthcare REIT by 75.2%, selling 111,862 shares and retaining 36,884 shares worth about $699,000.
• Sabra declared a quarterly dividend of $0.30 per share (annualized $1.20) with an ex-dividend date of May 15 and a yield of ~5.9%, though its dividend payout ratio is a high 190.48%.
• Sabra reported Q results with EPS $0.16 (in line) and revenue of $221.8M (above estimates), revenue rose 20.9% YoY, and it set FY2026 guidance of 1.550–1.590 EPS, while analysts' consensus is a "Moderate Buy" with a $22 price target.

Mitsubishi UFJ Trust & Banking Corp lowered its position in Sabra Healthcare REIT, Inc. (NASDAQ:SBRA - Free Report) by 75.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 36,884 shares of the real estate investment trust's stock after selling 111,862 shares during the period. Mitsubishi UFJ Trust & Banking Corp's holdings in Sabra Healthcare REIT were worth $699,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also added to or reduced their stakes in SBRA. Founders Capital Management bought a new stake in Sabra Healthcare REIT in the third quarter worth about $28,000. Danske Bank A S bought a new stake in Sabra Healthcare REIT in the third quarter worth about $30,000. Larson Financial Group LLC lifted its stake in Sabra Healthcare REIT by 42.3% in the third quarter. Larson Financial Group LLC now owns 1,860 shares of the real estate investment trust's stock worth $35,000 after purchasing an additional 553 shares during the last quarter. First Horizon Corp bought a new stake in Sabra Healthcare REIT in the fourth quarter worth about $44,000. Finally, Covestor Ltd raised its stake in shares of Sabra Healthcare REIT by 23,720.0% during the third quarter. Covestor Ltd now owns 2,382 shares of the real estate investment trust's stock valued at $45,000 after acquiring an additional 2,372 shares in the last quarter. Institutional investors own 99.40% of the company's stock.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. Citizens Jmp lifted their price target on shares of Sabra Healthcare REIT from $22.00 to $23.00 and gave the company a "market outperform" rating in a research note on Wednesday, February 18th. Scotiabank lifted their price target on shares of Sabra Healthcare REIT from $20.00 to $21.00 and gave the company a "sector perform" rating in a research note on Monday, March 2nd. Wall Street Zen raised shares of Sabra Healthcare REIT from a "sell" rating to a "hold" rating in a research note on Saturday. UBS Group lifted their price target on shares of Sabra Healthcare REIT from $20.00 to $21.00 and gave the company a "neutral" rating in a research note on Thursday, February 19th. Finally, Wells Fargo & Company lifted their price target on shares of Sabra Healthcare REIT from $21.00 to $22.00 and gave the company an "overweight" rating in a research note on Thursday, March 26th. Five investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the stock. Based on data from MarketBeat, Sabra Healthcare REIT has an average rating of "Moderate Buy" and a consensus price target of $22.00.

Sabra Healthcare REIT Stock Performance

Shares of SBRA stock opened at $20.38 on Wednesday. The firm has a market cap of $5.14 billion, a price-to-earnings ratio of 32.35, a PEG ratio of 1.64 and a beta of 0.67. The company's 50 day moving average is $20.24 and its 200 day moving average is $19.38. The company has a quick ratio of 4.72, a current ratio of 4.72 and a debt-to-equity ratio of 0.96. Sabra Healthcare REIT, Inc. has a 52-week low of $17.08 and a 52-week high of $21.07.

Sabra Healthcare REIT (NASDAQ:SBRA - Get Free Report) last issued its quarterly earnings data on Wednesday, April 29th. The real estate investment trust reported $0.16 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.16. The company had revenue of $221.75 million for the quarter, compared to analyst estimates of $209.20 million. Sabra Healthcare REIT had a net margin of 19.22% and a return on equity of 5.60%. Sabra Healthcare REIT's revenue was up 20.9% compared to the same quarter last year. During the same period last year, the company posted $0.37 earnings per share. Sabra Healthcare REIT has set its FY 2026 guidance at 1.550-1.590 EPS. On average, sell-side analysts anticipate that Sabra Healthcare REIT, Inc. will post 1.5 EPS for the current fiscal year.

Sabra Healthcare REIT Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, May 29th. Investors of record on Friday, May 15th will be issued a dividend of $0.30 per share. This represents a $1.20 annualized dividend and a yield of 5.9%. The ex-dividend date of this dividend is Friday, May 15th. Sabra Healthcare REIT's dividend payout ratio (DPR) is presently 190.48%.

About Sabra Healthcare REIT

Sabra Healthcare REIT, Inc NASDAQ: SBRA is a real estate investment trust that acquires, owns and operates net‐lease healthcare properties. Its diversified portfolio spans senior housing communities, skilled nursing and rehabilitation centers, outpatient medical facilities, medical office buildings, hospitals and life science properties. Sabra structures long‐term, triple‐net lease agreements with healthcare operators, providing stable rental income streams while allowing tenants to focus on patient care and operational excellence.

Serving a broad spectrum of care segments, Sabra's tenants include both regional and national providers of assisted living, independent living, memory care, post‐acute rehabilitation and research and development laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.